Chapters Transcript Video Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, discusses promising studies from the meeting Yeah. A couple of them include the destiny lung lung trial, which was the trial of Trust museum at Derek's Teak and I heard to anybody drug conjugate in patients with her two mutant lung cancer. So this is a subset of lung cancer characterized by genetic alteration where we do not have an approved targeted therapy. And there have been many, many attempts to develop targeted therapies in this space. Uh and most of them have not had a large degree of activity. I think the Trustees materialistic and trial stands a little bit in contrast to that has really the highest level of activity in terms of both response rate and progression free survival that has been seen to date. Um and uh does have toxicity lung disease, interstitial lung diseases, one of its uh limiting toxicities. But certainly on balance the efficacy for this population with no approved targeted therapies is favorable in my mind. Another, another important study presented was the empower 0101 Oh the adjuvant and Tess Eliza mab study uh in patients with surgically resected non small cell lung cancer. Um This study was initially presented at Asco in an additional uh degree of data shown at the asthma meeting to uh this past week. And and really highlights for the first time that there is a disease free survival benefit in patients who receive adjuvant immune checkpoint inhibition for surgically resected lung cancer. We've seen this in other diseases we have yet to see in the lung cancer. This is really the first demonstration of that. And the data at the meeting was interesting and it showed some more gradations in the PD L. One staining. So the patients that had the greater than 50% pd L one standing had the highest degree of benefit with no benefit in patients that are less. That had a low degree of PD L. One staining in sort of an intermediate in patients with the 1 to 49 percent Pd L one stating. So I think more to come from this study. Um And but but I think it clearly emphasizes the point that one can have a benefit and disease free survival from uh adjuvant uh Cecil is a map and of course we eagerly await to see what the impact is on overall survival. Another uh study that focused on another antibody drug conjugate targeting trope to called the S. 10 62 A this is an agent that's in clinical development and the presentation at Asthma focused really on patients who have target herbal genomic alterations who were treated with this agent. And most of the patients there at E. J. Far mutations and there was definitely some activity in that patient population. So, you know, this is a population of patients that are of course initially treated with E G F. R inhibitors. Um But having options for individuals once E G F R inhibitors are exhausted um is an important piece of information at the current time. We're using typically chemotherapy uh in this patient population. But having activity of the antibody drug conjugate I think was encouraging as well. And there is an ongoing trial of studying this agent specifically in patients with genotype, you know, with a target of genomic alterations who have exhausted genotype directed therapy to understand. Is it sort of across the board an effective strategy. Similarly, in patients who have do not have genomic alterations, there's a randomized trial versus chemotherapy of this particular agent. So I'm excited to see how this agent and antibiotic drug contacts in general evolve over the next uh next several years, because I think we're starting to see that this is really a new class of therapies for our patients. And I think trying to understand the exact therapeutic arenas for these agents will be important. Published Created by
